EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

The effects of intravenous immunoglobulin on intestinal inflammation: a systematic review of animal and clinical studies

Tiancheng Chu, Xin Yuan, Tong Wang, Wei Zhang, Xiaochen Yan, Changqing Li, Peng Jiang, Shengliang Ye, Li Ma, Pan Sun, Xi Du, Ping Fu und 1 weitere

PeerJ · 25.03.2026 · 14 · e21024

DOI: 10.7717/peerj.21024 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PeerJ, online erschienen am 25.03.2026. Verfasst von Tiancheng Chu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Inflammatory Bowel Diseases, Inflammation. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science & Technology Department of Sichuan Province, CAMS Innovation Fund for Medical Sciences, Science & Technology Department of Wenzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intestinal inflammation encompasses a range of conditions, including inflammatory bowel disease (IBD), radiation-induced enteritis, and chemotherapy- or toxin-induced epithelial injury. Although intravenous immunoglobulin (IVIg) is widely used in autoimmune and inflammatory disorders, its role in these forms of intestinal injury has not been systematically evaluated.

Objective

This systematic review aimed to summarize the existing animal and clinical evidence on the therapeutic effects of IVIg in intestinal inflammation.

Methods

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Four electronic databases (PubMed, Web of Science, Embase, and China National Knowledge Infrastructure) were systematically searched for studies published from January 1, 2000 to February 3, 2026. Eligible studies included animal and clinical investigations evaluating the role of IVIg in the context of intestinal inflammation. Data were narratively synthesized, and risk of bias was assessed using the SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) tool for animal studies and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) for non-randomized clinical studies.

Results

Ten studies were included: seven animal and three clinical studies. IVIg generally exhibited anti-inflammatory and epithelial-protective effects across models of Dextran Sulfate Sodium (DSS)-induced colitis, radiation-induced enteritis, chemotherapy-induced mucositis, and toxin-induced epithelial damage. Reported mechanisms included interleukin (IL)-10 signaling, Fcγ receptor modulation, ferroptosis inhibition, and microbiota-mediated immune regulation. Human data were restricted to small, retrospective, uncontrolled cohorts of patients with refractory or steroid-resistant IBD, often with contraindications to standard immunosuppressive therapy. In these studies, some patients experienced short-term clinical improvement, but responses were variable, long-term outcomes were frequently unsatisfactory, and the overall risk of bias was serious to critical.

Conclusion

Current animal and clinical data suggest that IVIg can modulate intestinal inflammation and epithelial injury but are insufficient to support its use as a standard therapy for IBD or other intestinal inflammatory conditions. At present, IVIg should be considered, at most, as an adjunctive or rescue option in carefully selected, refractory cases in which guideline-recommended therapies are ineffective or contraindicated. Further work is needed to improve the rigour and transparency of preclinical studies and to conduct small, well-designed prospective clinical studies in clearly defined niche indications to clarify any potential role of IVIg within the expanding therapeutic armamentarium for intestinal inflammation. PROSPERO ID (CRD420251051592).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousInflammatory Bowel DiseasesInflammationAnimalsHumansEnteritis

Stichwörter der Autor:innen

Animal modelsChemotherapy-induced mucositisClostridioides difficileInflammatory bowel diseaseIntestinal inflammationIntravenous immunoglobulinRadiation enteritisRefractory IBD

Substanzen

Immunoglobulins, Intravenous

Autor:innen und Institutionen

  • Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu, Sichuan, China.
  • Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu, Sichuan, China.
  • Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, Sichuan, China.
  • Beijing Tiantan Biological Products Co., Ltd., Beijing, China.

Förderung

  • Science & Technology Department of Sichuan Province
  • CAMS Innovation Fund for Medical Sciences
  • Science & Technology Department of Wenzhou
  • Scientific Research Project of Sichuan Medical Association

Zitieren

APA

Chu, T., Yuan, X., Wang, T., Zhang, W., Yan, X., Li, C., Jiang, P., Ye, S., Ma, L., Sun, P., Du, X., Fu, P., & Wang, Z. (2026). The effects of intravenous immunoglobulin on intestinal inflammation: a systematic review of animal and clinical studies. PeerJ, 14, e21024. https://doi.org/10.7717/peerj.21024

Vancouver

Chu T, Yuan X, Wang T, Zhang W, Yan X, Li C, et al. The effects of intravenous immunoglobulin on intestinal inflammation: a systematic review of animal and clinical studies. PeerJ. 2026;14:e21024. doi:10.7717/peerj.21024

BibTeX
@article{Chu2026,
  author = {Chu, Tiancheng and Yuan, Xin and Wang, Tong and Zhang, Wei and Yan, Xiaochen and Li, Changqing and Jiang, Peng and Ye, Shengliang and Ma, Li and Sun, Pan and Du, Xi and Fu, Ping and Wang, Zongkui},
  title = {The effects of intravenous immunoglobulin on intestinal inflammation: a systematic review of animal and clinical studies},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21024},
  doi = {10.7717/peerj.21024}
}
Kostenlos starten →